{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 455854971
| IUPAC_name = (''S'')-1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine
| image = Esmirtazapine 2D structure.svg
| width = 200
<!--Clinical data-->
| tradename = 
| pregnancy_category = 
| legal_status = Uncontrolled
| routes_of_administration = [[Mouth|Oral]]
<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism = Liver ([[CYP2D6]])<ref name="urlwww.page-meeting.org">{{cite web | url = http://www.page-meeting.org/pdf_assets/2259-posterPAGE2008_SP.pdf | title = A population analysis on the effects of the CYP2D6 deficiency on pharmacokinetics and exposure of esmirtazapine in healthy volunteers}}</ref>
| elimination_half-life = 
| excretion = 
<!--Identifiers-->
| index_label =
| index2_label = E. maleate
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 61337-87-9
| ATC_prefix = none
| ATC_suffix = 
| PubChem2 = 6451144
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2342166
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 4685R51V7M
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04055
| PubChem = 3085218
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB00316
<!--Chemical data-->
| C=17 | H=19 | N=3
| molecular_weight = 265.35 g/mol
| smiles = CN1CCN2c3c(cccn3)Cc4ccccc4[C@H]2C1
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3/t16-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RONZAEMNMFQXRA-MRXNPFEDSA-N
| melting_point = 114
| melting_high = 116
| solubility = Soluble in [[methanol]] and [[chloroform]]
}}

'''Esmirtazapine''' ('''ORG-50,081''') is a [[drug]] which was under development by [[Organon International|Organon]] for the treatment of [[insomnia]] and [[vasomotor]] [[symptom]]s (e.g., [[hot flash]]es) associated with [[menopause]].<ref name="urlFuture Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD -- Neurotransmitter.net">{{cite web | url = http://www.neurotransmitter.net/newdrugs.html | title = Future Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD -- Neurotransmitter.net | work = | accessdate = }}</ref><ref name="urlA Long-Term Safety Study of Org 50081 in Elderly Outpatients With Chronic Primary Insomnia (176005)(P05697) - Full Text View - ClinicalTrials.gov">{{cite web | url = http://clinicaltrials.gov/ct2/show/NCT00561574 | title = A Long-Term Safety Study of Org 50081 in Elderly Outpatients With Chronic Primary Insomnia (176005)(P05697) - Full Text View - ClinicalTrials.gov | format = | work = | accessdate = }}</ref><ref name="pmid18673166">{{cite journal |vauthors=Teegarden BR, Al Shamma H, Xiong Y | title = 5-HT(2A) inverse-agonists for the treatment of insomnia | journal = Current Topics in Medicinal Chemistry | volume = 8 | issue = 11 | pages = 969–76 | year = 2008 | pmid = 18673166 | doi = 10.2174/156802608784936700| url = }}</ref><ref name="pmid19775194">{{cite journal | author = Lewis V | title = Undertreatment of menopausal symptoms and novel options for comprehensive management | journal = Current Medical Research and Opinion | volume = 25 | issue = 11 | pages = 2689–98 |date=November 2009 | pmid = 19775194 | doi = 10.1185/03007990903240519 | url = http://informahealthcare.com/doi/abs/10.1185/03007990903240519}}</ref> Esmirtazapine is the (''S'')-(+)-[[enantiomer]] of [[mirtazapine]] and possesses similar overall [[pharmacology]], including [[inverse agonist]] actions at [[H1 receptor|H<sub>1</sub>]] and [[5-HT2 receptor|5-HT<sub>2</sub> receptor]]s and [[receptor antagonist|antagonist]] actions at [[alpha-2 adrenergic receptor|α<sub>2</sub>-adrenergic receptor]]s.<ref name="urlFuture Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD -- Neurotransmitter.net"/><ref name="isbn0-521-88663-5">{{cite book | title = Depression and bipolar disorder: Stahl's essential psychopharmacology | publisher = Cambridge University Press | location = Cambridge, UK | year = 2008 | pages = | isbn = 0-521-88663-5 | oclc = | doi = | url = https://books.google.com/books?id=zqvVZOea2JAC&lpg=PA112&dq=esmirtazapine&pg=PA112#v=onepage&q=&f=false}}</ref>  As of March 2010, Merck terminated internal clinical development program for esmirtazapine, for hot flashes and insomnia, for strategic reasons.<ref>http://www.merck.com/investors/financials/form-10-K-2009-final.pdf</ref>

==See also==
* [[Cidoxepin]]

==References==
{{Reflist|2}}

{{Antidepressants}}
{{Hypnotics}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Histamine receptor modulators}}
{{Serotonin receptor modulators}}
}}
{{Tricyclics}}

[[Category:Alpha-2 blockers]]
[[Category:Enantiopure drugs]]
[[Category:H1 receptor antagonists]]
[[Category:Noradrenergic and specific serotonergic antidepressants]]
[[Category:Serotonin antagonists]]
[[Category:Tetracyclic antidepressants]]


{{nervous-system-drug-stub}}
{{Organic-compound-stub}}